News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Insider Information

Ad hoc: Epigenomics AG Announces FDA Advisory Committee Meeting to Review Epi proColon®

Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) announces that the Company was informed by the U.S. Food and Drug Administration (FDA) via the premarket approval (PMA) review process for Epi proColon® that the Meeting of the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee has been tentatively scheduled for Tuesday, March 25th, […]

Read more

Ad hoc: Epigenomics AG issues EUR 500,000 in convertible bonds to Yorkville

Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516, OTC: EPGNY) announces today that the Company successfully issued convertible bonds with a nominal amount of EUR 500,000 to YA Global Master SVP Ltd. (“Yorkville”) excluding pre-emptive rights to existing shareholders. The bonds were issued at 95% of their nominal amount, carry no interest, have a term until […]

Read more

Correction Notification: Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) Correction of the announcement: Epigenomics AG increases share capital

PDF 29 KB   Correction notifaction of the announcement of Epigenomics AG (Frankfurt Prime Standard: ECX; ISIN: DE000A1K0516) according to § 15 WpHG as of October 28, 2013 – 9:00 pm CET Epigenomics erroneously announced yesterday its intention to increase its share capital by up to EUR 4,136,720.00 from the authorized capital. Instead, Epigenomics plans […]

Read more

Ad Hoc Epigenomics AG successfully completes private placement of newly issued shares

PDF 28 KB   Not for distribution in the United States Berlin, Germany, October 29, 2013 – Today the Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX;ISIN: DE000A1K0516) with the approval of the Supervisory Board has resolved on the increase of the Company’s share capital by EUR 660,260.00 from the authorized capital 2013/I against […]

Read more

Ad Hoc: Epigenomics AG increases share capital

PDF 58 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) announces that the Company’s Executive Board today with the approval of the Supervisory Board has resolved on an increase of the Company’s share capital by up to EUR 4,136,720 from the authorized capital. This capital increase follows a previous capital increase, published via ad […]

Read more

Ad hoc: Epigenomics and BioChain sign agreement for broad strategic collaboration in China

PDF 43 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) announces that it has signed an agreement with BioChain regarding a broad strategic collaboration of both companies. BioChain is a leading clinical diagnostics company in cancer and genetic tests in China and the US. As part of the agreed collaboration, which significantly expands the […]

Read more